106 related articles for article (PubMed ID: 29504239)
1. Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.
Mattila JP; Mirandola L; Chiriva-Internati M
J Biomed Mater Res B Appl Biomater; 2019 Jan; 107(1):29-36. PubMed ID: 29504239
[TBL] [Abstract][Full Text] [Related]
2. Formulation and evaluation of oral microparticulate ovarian cancer vaccines.
Tawde SA; Chablani L; Akalkotkar A; D'Souza C; Chiriva-Internati M; Selvaraj P; D'Souza MJ
Vaccine; 2012 Aug; 30(38):5675-81. PubMed ID: 22750042
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery.
Tawde SA; Chablani L; Akalkotkar A; D'Souza MJ
J Control Release; 2016 Aug; 235():147-154. PubMed ID: 27238440
[TBL] [Abstract][Full Text] [Related]
4. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.
Chiriva-Internati M; Yu Y; Mirandola L; Jenkins MR; Chapman C; Cannon M; Cobos E; Kast WM
PLoS One; 2010 May; 5(5):e10471. PubMed ID: 20485677
[TBL] [Abstract][Full Text] [Related]
5. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine.
Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M
Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201
[TBL] [Abstract][Full Text] [Related]
6. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
7. Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
Miyai M; Eikawa S; Hosoi A; Iino T; Matsushita H; Isobe M; Uenaka A; Udono H; Nakajima J; Nakayama E; Kakimi K
PLoS One; 2015; 10(8):e0136086. PubMed ID: 26291626
[TBL] [Abstract][Full Text] [Related]
8. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
Muraoka D; Kato T; Wang L; Maeda Y; Noguchi T; Harada N; Takeda K; Yagita H; Guillaume P; Luescher I; Old LJ; Shiku H; Nishikawa H
J Immunol; 2010 Sep; 185(6):3768-76. PubMed ID: 20733202
[TBL] [Abstract][Full Text] [Related]
10. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
12. A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients.
Battaglia A; Fossati M; Buzzonetti A; Scambia G; Fattorossi A
Immunol Lett; 2017 Nov; 191():35-39. PubMed ID: 28919454
[TBL] [Abstract][Full Text] [Related]
13. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
14. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
15. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams SF; Grimm AJ; Chiang CL; Mookerjee A; Flies D; Jean S; McCann GA; Michaux J; Pak H; Huber F; Neal C; Dangaj D; Bassani-Sternberg M; Rusakiewicz S; Facciabene A; Coukos G; Gimotty PA; Kandalaft LE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817208
[TBL] [Abstract][Full Text] [Related]
16. Oral microparticulate vaccine for melanoma using M-cell targeting.
D'Souza B; Bhowmik T; Shashidharamurthy R; Oettinger C; Selvaraj P; D'Souza M
J Drug Target; 2012 Feb; 20(2):166-73. PubMed ID: 21981679
[TBL] [Abstract][Full Text] [Related]
17. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
[TBL] [Abstract][Full Text] [Related]
18. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
19. Tumor vaccine for ovarian carcinoma targeting sperm protein 17.
Chiriva-Internati M; Wang Z; Salati E; Timmins P; Lim SH
Cancer; 2002 May; 94(9):2447-53. PubMed ID: 12015770
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma.
Iwahashi M; Katsuda M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Cancer Sci; 2010 Dec; 101(12):2510-7. PubMed ID: 20874827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
